Viking Therapeutics, Inc.
GB ˙ LSE ˙ US92686J1060
29,87 $ ↑0,55 (1,88%)
2026-06-04
DEL PRIS
SecurityGB:0VQA / Viking Therapeutics, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership3,013,928 shares
Latest Disclosed Value $ 98,073,265
Morgan Stanley reports 2.03% decrease in ownership of 0VQA / Viking Therapeutics, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 3,013,928 shares of Viking Therapeutics, Inc. (GB:0VQA) valued at $98,254,053 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 3,076,270 shares of Viking Therapeutics, Inc.. This represents a change in shares of -2.03% during the quarter. The current value of the position is $90,026,029 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VIKING THERAPEUTICS COM 92686J106 3,013,928 -62,342 -2.03 98,073 -9.38 0.0059
2026-05-27 2025-12-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 3,076,270 -652,847 -17.51 108,223 10.43 0.0065
2026-02-13 2025-12-31 13F VIKING THERAPEUTICS COM 92686J106 3,076,270 -652,847 108,223 0.0065
2026-05-27 2025-09-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 3,729,117 481,423 14.82 98,001 13.87 0.0059
2025-11-14 2025-09-30 13F VIKING THERAPEUTICS COM 92686J106 3,729,117 481,423 98,001 0.0059
2025-08-15 2025-06-30 13F VIKING THERAPEUTICS COM 92686J106 3,247,694 127,038 4.07 86,064 14.20 0.0056
2025-05-15 2025-03-31 13F VIKING THERAPEUTICS COM 92686J106 3,120,656 527,041 20.32 75,364 -27.79 0.0054
2025-05-15 2024-12-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 2,593,615 718,770 38.34 104,367 -12.07 0.0073
2025-02-14 2024-12-31 13F VIKING THERAPEUTICS COM 92686J106 2,593,615 718,770 104,367 0.0073
2025-05-14 2024-09-30 13F/A-2 VIKING THERAPEUTICS COM 92686J106 1,874,845 927,638 97.93 118,697 136.39 0.0086
2025-02-14 2024-09-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 1,874,845 927,638 118,697 0.0086
2024-11-14 2024-09-30 13F VIKING THERAPEUTICS COM 92686J106 1,874,845 927,638 118,697 0.0086
2025-05-14 2024-06-30 13F/A-2 VIKING THERAPEUTICS COM 92686J106 947,207 -52,164 -5.22 50,211 -38.73 0.0039
2024-10-17 2024-06-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 947,207 -52,164 50,211 0.0039
2024-08-14 2024-06-30 13F VIKING THERAPEUTICS COM 92686J106 947,207 -52,164 50,211 0.0039
2024-10-17 2024-03-31 13F/A-2 VIKING THERAPEUTICS COM 92686J106 999,371 -513,760 -33.95 81,948 191.02 0.0066
2024-08-16 2024-03-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 999,371 -513,760 81,948 0.0008
2024-05-15 2024-03-31 13F VIKING THERAPEUTICS COM 92686J106 999,371 -513,760 81,948 0.0066
2024-08-16 2023-12-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 1,513,131 622,449 69.88 28,159 185.62 0.0025
2024-02-13 2023-12-31 13F VIKING THERAPEUTICS COM 92686J106 1,513,131 622,449 28,159 0.0025
2023-11-15 2023-09-30 13F VIKING THERAPEUTICS COM 92686J106 890,682 -430,295 -32.57 9,860 -53.96 0.0010
2023-08-14 2023-06-30 13F VIKING THERAPEUTICS COM 92686J106 1,320,977 442,366 50.35 21,413 46.38 0.0021
2023-05-15 2023-03-31 13F VIKING THERAPEUTICS COM 92686J106 878,611 297,848 51.29 14,629 167.96 0.0016
2023-02-14 2022-12-31 13F VIKING THERAPEUTICS COM 92686J106 580,763 181,522 45.47 5,459 402.67 0.0006
2022-11-14 2022-09-30 13F VIKING THERAPEUTICS COM 92686J106 399,241 -261,927 -39.62 1,086 -43.20 0.0001
2022-10-27 2022-06-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 661,168 304,664 85.46 1,912 78.69 0.0002
2022-08-15 2022-06-30 13F VIKING THERAPEUTICS COM 92686J106 661,168 304,664 1,912 0.0002
2022-10-27 2022-03-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 356,504 131,861 58.70 1,070 3.48 0.0001
2022-05-13 2022-03-31 13F VIKING THERAPEUTICS COM 92686J106 356,504 131,861 1,070 0.0001
2022-02-14 2021-12-31 13F VIKING THERAPEUTICS COM 92686J106 224,643 -33,096 -12.84 1,034 -36.05 0.0001
2021-11-15 2021-09-30 13F VIKING THERAPEUTICS COM 92686J106 257,739 -190,852 -42.54 1,617 -39.82 0.0002
2021-08-23 2021-06-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 448,591 326,954 268.79 2,687 248.96 0.0004
2021-08-16 2021-06-30 13F VIKING THERAPEUTICS COM 92686J106 448,591 326,954 2,687 0.0001
2021-05-17 2021-03-31 13F VIKING THERAPEUTICS COM 92686J106 121,637 35,558 41.31 770 58.76 0.0001
2021-02-16 2020-12-31 13F VIKING THERAPEUTICS COM 92686J106 86,079 -256,645 -74.88 485 -75.68 0.0001
2020-11-13 2020-09-30 13F VIKING THERAPEUTICS COM 92686J106 342,724 173,320 102.31 1,994 63.18 0.0004
2020-08-14 2020-06-30 13F VIKING THERAPEUTICS COM 92686J106 169,404 89,521 112.07 1,222 227.61 0.0003
2020-05-26 2020-03-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 79,883 -150,568 -65.34 373 -79.82 0.0001
2020-05-15 2020-03-31 13F VIKING THERAPEUTICS COM 92686J106 79,883 -150,568 373 28.6542
2020-02-14 2019-12-31 13F VIKING THERAPEUTICS COM 92686J106 230,451 87,097 60.76 1,848 87.23 0.0004
2019-11-14 2019-09-30 13F VIKING THERAPEUTICS COM 92686J106 143,354 18,596 14.91 987 -4.64 0.0003
2019-08-14 2019-06-30 13F VIKING THERAPEUTICS COM 92686J106 124,758 -20,174 -13.92 1,035 -28.17 0.0003
2019-05-15 2019-03-31 13F VIKING THERAPEUTICS COM 92686J106 144,932 -264,156 -64.57 1,441 -53.95 0.0004
2019-02-14 2018-12-31 13F VIKING THERAPEUTICS COM 92686J106 409,088 250,538 158.02 3,129 13.29 0.0009
2019-04-23 2018-09-30 13F/A-2 VIKING THERAPEUTICS COM 92686J106 158,550 60,414 61.56 2,762 196.67 0.0007
2018-11-20 2018-09-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 158,550 0 2,762 0.0007
2018-11-14 2018-09-30 13F VIKING THERAPEUTICS COM 92686J106 158,550 60,414 2,762
2019-04-23 2018-06-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 98,136 85,255 661.87 931 1,562.50 0.0003
2018-08-14 2018-06-30 13F VIKING THERAPEUTICS COM 92686J106 98,136 85,255 931
2019-04-23 2018-03-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 12,881 12,881 -86.87 56 -93.98 0.0000
2018-05-14 2018-03-31 13F VIKING THERAPEUTICS COM 92686J106 12,881 12,881 56
2017-08-11 2017-06-30 13F VIKING THERAPEUTICS COM 92686J106 0 -398 -100.00 0 -100.00
2017-05-22 2017-03-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 398 -15,241 -97.46 1 -94.74 0.0000
2017-05-12 2017-03-31 13F VIKING THERAPEUTICS COM 92686J106 398 1
2017-02-22 2016-12-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 15,639 15,027 2,455.39 19 1,800.00 0.0000
2017-02-13 2016-12-31 13F VIKING THERAPEUTICS COM 92686J106 15,639 19
2016-11-10 2016-09-30 13F VIKING THERAPEUTICS COM 92686J106 612 17 2.86 1 0.00 0.0000
2016-08-12 2016-06-30 13F VIKING THERAPEUTICS COM 92686J106 595 578 3,400.00 1 0.00 0.0000
2016-05-12 2016-03-31 13F VIKING THERAPEUTICS COM 92686J106 17 0 0.00 0 -100.00 0.0000
2016-02-09 2015-12-31 13F VIKING THERAPEUTICS COM 92686J106 17 17 0.00 0 0.0000
2016-02-08 2015-09-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 0 -16 -100.00 0 0.0000
2015-08-12 2015-06-30 13F VIKING THERAPEUTICS COM 92686J106 16 16 0 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.